Omni Bio Pharmaceutical (CE) Stock Price - OMBP

0.0004
0.00 (0.0%)
0.0004
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Omni Bio Pharmaceutical Inc (CE) OMBP OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.0004 0.00 0.00 0.00 0.0004 20:00:00
Bid Price Ask Price Spread Spread % News
0.01 0.012 0.002 16.67% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0004 USD

Omni Bio Pharmaceutical (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 20.02k 50.06M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
696.00 $ - 0.00% - -

more financials information »

Omni Bio Pharmaceutical (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OMBP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00050.00050.00040.000435,000-0.0001-20.0%
1 Month0.00040.00050.00040.000419,1610.000.0%
3 Months0.010.0150.00010.00515628,455-0.0096-96.0%
6 Months0.00030.0150.00010.002351945,2720.000133.33%
1 Year0.01390.0170.00010.004181225,428-0.0135-97.12%
3 Years0.0210.03860.00010.013605621,190-0.0206-98.1%
5 Years0.02510.130.00010.023118329,162-0.0247-98.41%

Omni Bio Pharmaceutical (CE) Description

Omni Bio is an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory disease. The Company?s technology platform, AAT-Fc, is a recombinant version of plasma-derived alpha-1 antitrypsin (p-AAT), a naturally occurring human protein that is currently commercialized as an intravenous supplementation therapy for AAT-deficient individuals. Omni Bio is capitalizing on emerging scientific evidence of AAT's fundamental role in mediating multiple anti-inflammatory and tissue protective pathways to develop a first-in-class therapeutic to address a broad array of new clinical opportunities. Omni Bio?s recombinant AAT-Fc offers several potential advantages over current p-AAT products, including superior potency, longer half-life, improved safety and easy-to-administer subcutaneous dosing, as well as significantly enhanced manufacturing scalability. Omni Bio intends to exploit AAT-Fc?s enhanced product potential to address multiple, high-value immune-mediated inflammatory disease indications, such as Type 1 diabetes, graft versus host disease and treatment refractory gout. The Company holds broad intellectual property covering both recombinant and plasma-derived AAT for these and other indications.


Your Recent History
USOTC
OMBP
Omni Bio P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.